Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program
Michael J. DiStefano,Antal Zemplenyi,Kelly E. Anderson,Nicholas D. Mendola,Kavita V. Nair,Robert Brett McQueen
DOI: https://doi.org/10.1080/14737167.2023.2283584
2023-11-14
Expert Review of Pharmacoeconomics & Outcomes Research
Abstract:INTRODUCTION: The United States has begun assessing the value of pharmaceuticals to inform negotiated prices in the Medicare program. Given strong political objections in the United States to the use of QALYs, Medicare will need to adopt an alternative approach to measuring value.AREAS COVERED: In this narrative review, we identified six alternative approaches to measuring value (equal value life-years, health years in total, generalized risk-adjusted cost-effectiveness, severity weighting based on absolute or proportional shortfall, comparative effectiveness based on conventional clinical endpoints, and comparative effectiveness based on both conventional endpoints and patient-centric value elements) and five criteria for assessing these approaches (responsiveness to concerns about discrimination, feasibility, transparency, flexibility, and the ability to incorporate factors beyond traditional value elements).EXPERT OPINION: Four of the alternatives are broadly aligned with the cost-effectiveness framework, but none fully addresses all aspects of the stated concerns that QALYs may be used to unintentionally implement discrimination. We note, however, that the extent to which these concerns lead to discrimination in practice is unknown. Finally, we recommend an approach for measuring value in terms of comparative effectiveness that combines quantitative ranking and weighting of distinct criteria (including patient-centric value elements) with deliberation.
pharmacology & pharmacy,health care sciences & services,health policy & services